Breakthrough in Oncology: Novel ADC Rolditamig Deuderuxtecan Triples Progression-Free Survival in HER2-Low Breast Cancer
MADRID — In a landmark development for the treatment of metastatic breast cancer, researchers have unveiled results from the phase III APEX-Breast01 trial, demonstrating that the novel antibody-drug conjugate (ADC)…












